Results of early benefit assessment (AMNOG) and additional treatment costs: is there a relationship?

descriptionPublicationkeyboard_double_arrow_right Conference object 01 Jan 2014Embargo end date: 18 Nov 2014 English Publisher:German Medical Science GMS Publishing House; Düsseldorf

Authors: Herr, D; Thürmann, PA;

doi: 10.3205/14gaa29

Results of early benefit assessment (AMNOG) and additional treatment costs: is there a relationship?

- Summary
- Subjects
- Metrics

Abstract

Background: Total expenditures for pharmaceuticals in Germany in 2012 added up to approx. 43 billion euros [ref:1] with a considerably increasing share of patented drugs during the last 20 years [ref:2]. Since 2011 an early benefit assessment in accordance with the AMNOG legislation[for full text, please go to the a.m. URL]

21. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie, 9. Deutscher Pharmakovigilanztag

Keywords

ddc: 610, 610 Medical sciences; Medicine

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average